“Incidence and Factors Associated With Adverse Drug Reactions in a Cohort of Individuals Starting Dolutegravir or Efavirenz ”. 2022. Research, Society and Development 11 (4): e0811426250. https://doi.org/10.33448/rsd-v11i4.26250.